Stock page

Natera Inc (NTRA)

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Quote snapshot

$194.24
Daily change: —
ExchangeNAS
Updated2026-05-09T03:33:38.998767Z

Price chart

Price history

Name
Revenue
Cost Of Goods Sold
Gross Profit
Gross Margin %
Research Development
Selling General Admin Expense
Depreciation Depletion Amortization
Other Operating Expense
Total Operating Expense
Operating Income
Operating Margin
Interest Income
Interest Expense
Other Income Expense
Other Income Minority Interest
Other Net Income Loss
Ebit
Ebitda
Ebitda Margin
Pretax Income
Tax Provision
Tax Rate
Net Income Continuing Operations
Net Income Discontinued Operations
Net Income
Net Income Including Noncontrolling Interests
Is Preferred Dividends
Shares Outstanding
Eps Basic
Eps Diluted
Net Margin

SEC filings

Latest 10-K filing table

Date Form Accession Link